Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • IR-1061: NIR-II Fluorescent Dye Aggregation for Precision In

    2026-05-14

    IR-1061: NIR-II Fluorescent Dye Aggregation for Precision In Vivo Imaging

    Introduction

    The drive to visualize and treat biological phenomena deep within living tissues has elevated the importance of near infrared fluorescent dyes in biomedical research. Among the myriad of available fluorophores, IR-1061 stands out as a chemically engineered, organic dye optimized for in vivo optical imaging. Its strong fluorescence in the NIR-II window (1000–1700 nm) enables researchers to overcome the limitations of tissue autofluorescence and scattering, facilitating both advanced imaging and innovative synergistic therapies (source: paper). This article examines a critical—yet underexplored—aspect of IR-1061: how its molecular aggregation state, particularly H-aggregation, directly dictates its optical and photothermal performance in live subjects.

    The Molecular Foundation: IR-1061’s Physical and Chemical Attributes

    IR-1061 is a solid-state, boron-based organic dye with the formula C44H34BClF4S2 and a molecular weight of 749.13. It is uniquely soluble at concentrations ≥25.65 mg/mL in DMSO, but insoluble in ethanol and water, making careful preparation essential for reproducibility (source: product_spec). To preserve its photoactivity, IR-1061 must be stored tightly sealed and desiccated at -20°C, and solutions should be freshly prepared to avoid degradation (source: product_spec). These properties make IR-1061 a robust but technically demanding tool for researchers seeking high signal-to-background ratios in deep tissue molecular imaging.

    From Photophysics to Function: The Role of Aggregation State

    Unlike many fluorophores, IR-1061’s performance is profoundly shaped by its aggregation state—specifically, whether molecules are dispersed (free), J-aggregated, or H-aggregated. The distinction is not just academic. In the H-aggregated state, IR-1061 molecules stack face-to-face, modulating their absorption/emission spectra and enabling efficient photothermal conversion. This property underpins dual-modality applications: bright, high-contrast fluorescence imaging and photothermal therapy (PTT) (source: paper).

    Protocol Parameters

    • assay | dye concentration | ≥25.65 mg/mL in DMSO | maximizes solubility for consistent NIR-II signal | product_spec
    • assay | storage temperature | -20°C (sealed, desiccated) | preserves fluorescence and stability | product_spec
    • assay | solution stability | Use freshly prepared; avoid long-term storage | prevents degradation and signal loss | product_spec
    • assay | solvent compatibility | Insoluble in ethanol and water | ensures experimental consistency | product_spec
    • assay | aggregation state control | Use lipid nanocarriers or membrane mimics to induce H-aggregation | enhances PTT and imaging performance | paper

    Reference Insight Extraction: H-Aggregation as a Translational Innovation

    The most significant innovation highlighted in the seminal study by Yu et al. (paper) is the deliberate induction and transfer of IR-1061’s H-aggregated state from lipid nanocarrier to tumor cell membrane. Through molecular dynamics simulations and in vivo validation, the authors demonstrate that H-aggregated IR-1061, when embedded in a specialized liposome, not only maintains robust NIR-II fluorescence for optical imaging but also enables efficient photothermal conversion for synergistic cancer therapy. Critically, functionalizing the liposome with a targeting peptide (RR9) allows for the direct transfer of the H-aggregate state onto tumor cell membranes, preserving these properties in situ.

    This is a practical breakthrough for assay design: rather than treating aggregation as a passive outcome, researchers can actively control and exploit IR-1061’s molecular arrangement to achieve dual imaging-therapeutic functions. The implication is clear: the optimal use of IR-1061 demands careful consideration of both formulation and biological context, as the dye’s microenvironment fundamentally governs its utility in vivo.

    Comparative Analysis: IR-1061 versus Alternative Approaches

    Several recent reviews have explored the mechanistic and assay guidance for IR-1061 and related NIR dyes. For example, the article "IR-1061: Advanced Mechanistic Insights for NIR-II Imaging Success" delves into the detailed photophysical mechanisms and practical troubleshooting for IR-1061. However, our analysis advances the field by focusing on the active engineering of aggregation states as a lever for performance, rather than solely on post-hoc optimization or troubleshooting.

    Moreover, studies such as "IR-1061 Near Infrared Fluorescent Dye: Deep Tissue Imaging Reinvented" emphasize actionable protocols and troubleshooting strategies for maximizing deep tissue visualization. In contrast, this article uniquely addresses the translational implications of aggregation-state manipulation—specifically H-aggregation—for both signal generation and therapeutic synergy, providing a framework for informed protocol design rather than a checklist for assay troubleshooting.

    Alternative materials, such as copper-based MOFs for CDT imaging (see this study), leverage metal–organic frameworks for different imaging and therapeutic mechanisms. While these systems excel in catalytic efficiency and ROS generation, they lack the organic biocompatibility and dual-modality potential offered by IR-1061 when its aggregation is precisely managed. Thus, the choice between these modalities should be informed by specific application and safety requirements.

    Advanced Applications: IR-1061 as a Fluorescent Dye for Biomedical Research and Synergistic Therapy

    By exploiting the H-aggregated state, IR-1061 emerges as a leading fluorescent dye for in vivo imaging with transformative potential in cancer research. In the referenced study, the lipid nanosystem enabled high signal-to-background ratio (SBR) visualization of both tumor tissues and blood vessels, a feat attributed to the enhanced photophysical properties of H-aggregated IR-1061 (source: paper). This dual channel function supports both real-time diagnosis and photothermal ablation within the same platform, a property that traditional fluorophores or inorganic nanoparticles seldom achieve in a biocompatible, clinically translatable format.

    Key workflow recommendations for researchers seeking to deploy IR-1061 in advanced molecular imaging include:

    • Utilize DMSO for initial dissolution and immediately formulate into lipid-based or membrane-mimetic carriers to induce controlled aggregation.
    • Assess the biological microenvironment, as protein-rich or membrane-dense settings can modulate aggregation and thus performance.
    • Prioritize freshly prepared solutions and minimize freeze-thaw cycles to maintain optimal fluorescence and photothermal capacity.

    By integrating these protocol nuances, researchers can harness IR-1061 not just as a static probe, but as a dynamic tool whose performance can be tuned by environmental engineering—a shift from reagent-based to system-based assay design.

    Practical Implications for Protocol Design: What the Evidence Means

    The translational insight from Yu et al. is that the deliberate engineering of IR-1061's aggregation state is not merely a matter of chemical curiosity, but a practical requirement for realizing its full imaging and therapeutic potential. For those designing new fluorescent dye-based assays, this entails:

    • Incorporating lipid nanocarriers or membrane-mimetic systems to stabilize H-aggregation.
    • Choosing application-specific targeting ligands to ensure delivery of the aggregated dye to the desired cellular compartment.
    • Carefully validating aggregation state and fluorescence/photothermal output via HPLC and NMR prior to in vivo deployment (source: product_spec).

    This protocol perspective is distinct from prior guides that emphasized troubleshooting or bulk signal optimization, representing a maturation in how advanced near infrared fluorescent dyes are deployed for molecular imaging and therapy.

    Conclusion and Future Outlook

    IR-1061, available from APExBIO, exemplifies a new generation of organic NIR-II fluorescent dyes whose utility is defined as much by their supramolecular state as by their chemical identity. The ability to induce and transfer H-aggregation opens new avenues for high-contrast imaging and synergistic photothermal therapy—outcomes that are unattainable with traditional, aggregation-insensitive probes (source: paper).

    Looking forward, further development of targeted lipid nanocarriers and real-time monitoring of aggregation state in vivo will be crucial for standardizing and extending IR-1061’s applications across preclinical and, potentially, clinical domains. As the evidence base grows, the rational design principles articulated here—active aggregation control, context-aware formulation, and rigorous validation—will serve as the foundation for next-generation molecular imaging platforms.